GlassScriptPhysician profile
Jaspreet K Ghumman
NPI 1225278054
$7,284.31
in general payments reported to CMS, 2019-2025
30 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $317 · 2021: $628 · 2022: $1,388 · 2023: $1,379 · 2024: $1,426 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,143.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,951.45 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,046.86 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $770.80 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $726.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $655.09 | 2019-2025 | |
| Gilead Sciences, INC. | $300.43 | 2019-2025 | |
| Qol Medical, LLC | $273.24 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $234.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $169.23 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $160.44 | 2022-2024 | Ibsrela |
| Celgene Corporation | $135.12 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $134.44 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $127.38 | 2021-2025 | Rebyota |
| Braintree Laboratories, INC. | $103.45 | 2019-2023 | Suflave |
| Merck Sharp & Dohme LLC | $57.54 | 2021-2024 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.41 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $41.61 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.15 | 2023 | Cyltezo |
| Lilly USA, LLC | $39.35 | 2024-2025 | Omvoh |
| Allergan, INC. | $38.01 | 2019-2020 | |
| Ucb, INC. | $37.60 | 2019 | |
| Cook Medical LLC | $32.72 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $28.89 | 2024 | Iqirvo |
| Romark Laboratories, Lc | $27.94 | 2019 | |
| Daiichi Sankyo INC. | $22.77 | 2025 | Injectafer |
| Ironwood Pharmaceuticals, INC | $18.75 | 2021 | |
| Vivus LLC | $17.18 | 2025 | Qsymia |
| Celltrion USA INC. | $16.73 | 2025 | Vegzelma |
| Amgen INC. | $16.41 | 2022 | |
| Lucid Diagnostics INC. | $15.93 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Ghumman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.